{"id":67284,"date":"2026-06-04T13:17:51","date_gmt":"2026-06-04T05:17:51","guid":{"rendered":"https:\/\/flcube.com\/?p=67284"},"modified":"2026-06-04T13:17:53","modified_gmt":"2026-06-04T05:17:53","slug":"shandong-boan-biotech-licenses-ba5101-dulaglutide-biosimilar-for-us-market-first-global-copycat-of-trulicity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67284","title":{"rendered":"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shandong Boan Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>) announced a <strong>licensing agreement<\/strong> with an undisclosed pharmaceutical company, granting <strong>commercialization rights<\/strong> for its <strong>BA5101 dulaglutide biosimilar<\/strong> in the <strong>United States<\/strong> market.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-financial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner<\/strong><\/td><td>Undisclosed US pharmaceutical company<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>United States<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BA5101 (dulaglutide biosimilar)<\/td><\/tr><tr><td><strong>Compensation<\/strong><\/td><td>Upfront payment + milestone payments + sales royalties<\/td><\/tr><tr><td><strong>Disclosure<\/strong><\/td><td>Financial terms remain confidential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction enables Boan Bio to monetize its biosimilar asset without establishing a direct US commercial presence, while providing its partner immediate access to a clinically validated GLP-1 receptor agonist with proven efficacy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-status-amp-market-position\" class=\"wp-block-heading\">Regulatory Status &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approval Date:<\/strong> August 2025 (China)<\/li>\n\n\n\n<li><strong>Global Status:<\/strong> First and only approved dulaglutide biosimilar worldwide<\/li>\n\n\n\n<li><strong>Reference Product:<\/strong> Eli Lilly&#8217;s Trulicity\u00ae (dulaglutide)<\/li>\n\n\n\n<li><strong>Patent Landscape:<\/strong> Navigated complex patent thicket surrounding original molecule<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">BA5101&#8217;s Chinese approval established Boan Bio as the pioneer in the dulaglutide biosimilar category, giving the company valuable real-world evidence and manufacturing experience ahead of competitors.<\/p>\n\n\n\n<h2 id=\"h-clinical-profile-amp-therapeutic-differentiation\" class=\"wp-block-heading\">Clinical Profile &amp; Therapeutic Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Long-acting GLP-1 receptor agonist (once-weekly)<\/li>\n\n\n\n<li><strong>Primary Indication:<\/strong> Type 2 diabetes mellitus<\/li>\n\n\n\n<li><strong>Key Benefits:<\/strong><\/li>\n\n\n\n<li>Stable reduction of blood glucose and HbA1c levels<\/li>\n\n\n\n<li>Significant reduction in major adverse cardiovascular events<\/li>\n\n\n\n<li>Meaningful body weight reduction<\/li>\n\n\n\n<li>Renal protective effects<\/li>\n\n\n\n<li>Low hypoglycemia risk<\/li>\n\n\n\n<li>Favorable gastrointestinal tolerability<\/li>\n\n\n\n<li>Improved treatment adherence through once-weekly dosing<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The comprehensive clinical benefits position BA5101 as a potential first-line biologic option for type 2 diabetes patients requiring injectable therapy.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-outlook\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US GLP-1 Market Size:<\/strong> Estimated at $15+ billion annually<\/li>\n\n\n\n<li><strong>Trulicity Sales (2025):<\/strong> $7.2 billion globally (Eli Lilly annual report)<\/li>\n\n\n\n<li><strong>Biosimilar Pricing Premium:<\/strong> Expected 15-30% discount versus reference product<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Approximately 37 million Americans with diabetes, with 90-95% having type 2 diabetes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Boan Bio&#8217;s entry into the US market through this licensing arrangement represents a significant milestone for Chinese biopharmaceutical companies seeking global commercialization of complex biologics. The deal structure mitigates regulatory and commercial risks while providing meaningful revenue potential through the tiered payment model.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial expectations and market opportunities for BA5101. Actual results may differ due to regulatory approvals, market adoption, competitive dynamics, and pricing pressures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[43,220,39,1024],"class_list":["post-67284","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biosimilars","tag-boan-biotechnology","tag-diabetes","tag-hkg-6955"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical company, granting commercialization rights for its BA5101 dulaglutide biosimilar in the United States market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67284\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity\" \/>\n<meta property=\"og:description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical company, granting commercialization rights for its BA5101 dulaglutide biosimilar in the United States market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67284\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T05:17:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T05:17:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67284#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67284\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity\",\"datePublished\":\"2026-06-04T05:17:51+00:00\",\"dateModified\":\"2026-06-04T05:17:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67284\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Boan Biotechnology\",\"Diabetes\",\"HKG: 6955\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67284#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67284\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67284\",\"name\":\"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-04T05:17:51+00:00\",\"dateModified\":\"2026-06-04T05:17:53+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical company, granting commercialization rights for its BA5101 dulaglutide biosimilar in the United States market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67284#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67284\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67284#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical company, granting commercialization rights for its BA5101 dulaglutide biosimilar in the United States market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67284","og_locale":"en_US","og_type":"article","og_title":"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity","og_description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical company, granting commercialization rights for its BA5101 dulaglutide biosimilar in the United States market.","og_url":"https:\/\/flcube.com\/?p=67284","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-04T05:17:51+00:00","article_modified_time":"2026-06-04T05:17:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67284#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67284"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity","datePublished":"2026-06-04T05:17:51+00:00","dateModified":"2026-06-04T05:17:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67284"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Boan Biotechnology","Diabetes","HKG: 6955"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67284#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67284","url":"https:\/\/flcube.com\/?p=67284","name":"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-04T05:17:51+00:00","dateModified":"2026-06-04T05:17:53+00:00","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical company, granting commercialization rights for its BA5101 dulaglutide biosimilar in the United States market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67284#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67284"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67284#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market \u2013 First Global Copycat of Trulicity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67284"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67284\/revisions"}],"predecessor-version":[{"id":67289,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67284\/revisions\/67289"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}